Drug Profile
Brilacidin - Alfasigma/Innovation Pharmaceuticals
Alternative Names: Brilacidin tetrahydrochloride; Brilacidin-Ocular; Brilacidin-OM; Brilacidin-Otic; Defensin-mimetic - Innovation Pharmaceuticals; HDP-mimic - Innovation Pharmaceuticals; Host defense protein-mimic - Innovation Pharmaceuticals; PMX-30063Latest Information Update: 26 Jun 2023
Price :
$50
*
At a glance
- Originator PolyMedix
- Developer Innovation Pharmaceuticals
- Class Amides; Anti-infectives; Anti-inflammatories; Antiacnes; Antibacterials; Antivirals; Foot disorder therapies; Guanidines; Peptidomimetics; Pyrimidines; Pyrrolidines; Skin disorder therapies; Small molecules
- Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators; Immunomodulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Phase II COVID 2019 infections; Skin and soft tissue infections; Stomatitis; Ulcerative proctitis
- Preclinical Alphavirus infections; Bunyavirus infections; Coronavirus infections; Ebola virus infections; Marburg virus disease; Nipah virus infections; West Nile virus infections; Zika virus infection
- No development reported Acne; Atopic dermatitis; Diabetic foot ulcer; Hidradenitis suppurativa; Inflammatory bowel diseases; Otitis; Wounds
- Discontinued Intestinal infections; Ophthalmic infections; Ulcerative colitis
Most Recent Events
- 21 Jun 2023 Innovation Pharmaceuticals has patents pending for Brilacidin in fungal diseases in USA
- 21 Jun 2023 Innovation Pharmaceuticals receives notice of allowance for patent covering arylamide compounds for treatment of viral infections in USA
- 06 Jun 2023 Innovation Pharmaceuticals has patent protection for Brilacidin in the US